Document is current
Any future updates will be listed below
-
Authors
Nayar, Saba https://orcid.org/0000-0002-4350-110X
Turner, Jason D. https://orcid.org/0000-0002-5423-5302
Asam, Saba
Fennell, Eanna https://orcid.org/0000-0002-1280-3439
Pugh, Matthew https://orcid.org/0000-0002-6324-661X
Colafrancesco, Serena
Berardicurti, Onorina
Smith, Charlotte G.
Flint, Joe
Teodosio, Ana https://orcid.org/0000-0002-1386-6730
Iannizzotto, Valentina
Gardner, David H.
van Roon, Joel https://orcid.org/0009-0009-5571-2324
Korsunsky, Ilya https://orcid.org/0000-0003-4848-3948
Howdle, Dawn
,
Brenner, Michael
Coles, Mark
Powrie, Fiona M.
Raychaudhuri, Soumya
Frei, Andreas P. https://orcid.org/0000-0002-9996-8251
Lassen, Kara G.
Bowman, Simon J.
Ng, Wan-Fai
Croft, Adam P. https://orcid.org/0000-0002-9487-0511
Filer, Andrew https://orcid.org/0000-0001-8164-6249
Fisher, Benjamin A.
Buckley, Christopher D. https://orcid.org/0000-0001-6924-6402
Barone, Francesca https://orcid.org/0000-0002-5287-9614
-
Funding
Funding for this research was provided by:
Details provided in the manuscript
- License Information
-
More Information
Article History
Received: 20 October 2022
Accepted: 18 November 2024
First Online: 2 January 2025
Competing interests
: F.B. is an employee of Candel Therapeutics. C.D.B is the founder of Mestag Therapeutics. B.A.F. has undertaken consultancy for: Novartis, BMS, Servier, Galapagos, Roche, UCB, Sanofi, Janssen, A.Z., Otsuka, Amgen, Kiniksa and received research funding from Janssen, Servier, Galapagos, and Celgene. A.F. has consulted for Janssen and Sonoma, and has received research funding from: BMS, Roche, UCB, Nascient, Mestag, GSK, and Janssen. S.J.B. has undertaken consultancy for: Abbvie, Amgen, Argenx, Aurinia, Bain, BMS, EcoR1, Iqvia, J&J/Janssen, Kiniksa & Novartis. K.G.L. and A.P.F. are employees of F. Hoffmann-La Roche Ltd. The remaining authors declare no competing interests.
